Tech Company Financing Transactions
Armetheon Funding Round
On 2/5/2015, Armetheon secured $24.3 million in Series B financing from Capital TEN II, Amkey Ventures and CDIB Bioscience.
Transaction Overview
Company Name
Announced On
2/5/2015
Transaction Type
Venture Equity
Amount
$24,300,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead clinical candidate, tecarfarin, which is being investigated as a novel vitamin-K-antagonist (VKA) oral anticoagulant that avoids adverse drug reactions associated with the current standard-of-care, warfarin
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3375 Scott Blvd. 306
Santa Clara, CA 95054
USA
Santa Clara, CA 95054
USA
Phone
Website
Email Address
Not Recorded
Overview
Armetheon, Inc., is a privately held, San Francisco Bay area-based clinical stage biopharmaceutical company focused on the development of novel drug.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ken Kengatharan
Chief Scientific Officer
Pascal Druzgala
VP - Finance
David Buffenbarger
VP - General Counsel
Elizabeth Ahrens
VP - Human Resources
Lisa Stemmerich
VP - Product Management
Andrew Lam
Browse more venture capital transactions:
Prev: 2/5/2015: ClusterHQ venture capital transaction
Next: 2/5/2015: Velano Vascular venture capital transaction
Share this article
News on VC Transactions
We document every notable VC transaction. All VC database entries reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs